On April 16, 2025 Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, reported the upcoming presentation of new preclinical data from studies of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School (Press release, Edgewood Oncology, APR 16, 2025, View Source [SID1234651959]). These data will be featured in poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will showcase the therapeutic potential of BTX-A51, a first-in-class dual inhibitor of casein kinase 1 alpha (CK1a) and cyclin-dependent kinases 7 and 9 (CDK7/9), in preclinical models of human liposarcoma and CIC-rearranged sarcoma—a rare and aggressive cancer that tends to affect pediatric and younger adult patients.
Presentation Details:
Poster 1:
Title: Therapeutic Potential of Combined Targeting of Casein Kinase 1 alpha (CK1 alpha) and CDK7/9 with the Inhibitor BTX-A51 in Human Liposarcomas
Session Category: Experimental and Molecular Therapeutics
Session Title: Identification of Molecular Targets 1
Date and Time: Monday, April 28, 2025 | 2:00 PM – 5:00 PM CT
Location: Poster Section 19 | Board Number: 10
Abstract Number: 2980
These data support the ongoing phase 1 study of BTX-A51 in patients with advanced MDM2-amplified liposarcoma. Additional details about the study can be found at clinicaltrials.gov under the identifier NCT06414434.
Poster 2:
Title: Preclinical efficacy of the CK1 alpha/CDK7/CDK9 inhibitor BTX-A51 in CIC-rearranged sarcoma
Session Category: Experimental and Molecular Therapeutics
Session Title: Protein Kinases and Phosphatases as Targets for Therapy
Date and Time: Wednesday, April 30, 2025 | 9:00 AM – 12:00 PM CT
Location: Poster Section 24 | Board Number: 3
Abstract Number: 6941